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Arterial medial calciﬁcation (AMC) is prevalent in patients with chronic kidney disease (CKD) and con-
tributes to elevated risk of cardiovascular events and mortality. Vascular smooth muscle cells (VSMCs) to
osteogenic transdifferentiation (VOT) in a high-phosphate environment is involved in the pathogenesis
of AMC in CKD. WNT/β-catenin signaling is indicated to play a crucial role in osteogenesis via promoting
Runx2 expression in osteoprogenitor cells, however, its role in Runx2 regulation and VOT remains in-
completely clariﬁed. In this study, Runx2 was induced and β-catenin was activated by high-phosphate in
VSMCs. Two forms of active β-catenin, dephosphorylated on Ser37/Thr41 and phosphorylated on Ser675
sites, were upregulated by high-phosphate. Activation of β-catenin, through ectopic expression of sta-
bilized β-catenin, inhibition of GSK-3β, or WNT-3A protein, induced Runx2 expression, whereas blockade
of WNT/β-catenin signaling with Porcupine (PORCN) inhibitor or Dickkopf-1 (DKK1) protein inhibited
Runx2 induction by high-phosphate. WNT-3A promoted osteocalcin expression and calcium deposition
in VSMCs, whereas DKK1 ameliorated calciﬁcation of VSMCs induced by high-phosphate. Two functional
T cell factor (TCF)/lymphoid enhancer-binding factor binding sites were identiﬁed in the promoter region
of Runx2 gene in VSMCs, which interacted with TCF upon β-catenin activation. Site-directed mutation of
each of them attenuated Runx2 response to β-catenin, and deletion or destruction of both of them
completely abolished this responsiveness. In the aortic tunica media of rats with chronic renal failure,
followed by AMC, Runx2 and β-catenin was induced, and the Runx2 mRNA level was positively asso-
ciated with the abundance of phosphorylated β-catenin (Ser675). Collectively, our study suggested that
high-phosphate may activate WNT/β-catenin signaling through different pathways, and the activated
WNT/β-catenin signaling, through direct downstream target Runx2, could play an important role in
promoting VOT and AMC.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Arterial medial calciﬁcation (AMC), also known as Mön-
ckeberg's medial sclerosis, is one of major pathological types of
vascular calciﬁcation, which is highly prevalent in patients with
chronic kidney disease (CKD) [1–4]. Hyperphosphatemia, a com-
mon clinical feature in patients with CKD and subsequent end
stage renal disease, is germane to the development and progres-
sion of AMC and is identiﬁed as a major risk factor which is closelyInc. This is an open access article u
s; AMC, arterial medial calci-
nsity lipoprotein receptor-re-
, Porcupine
.related to cardiovascular morbidity and mortality [5–7]. Although
the pathogenesis of AMC hasn't as yet been elucidated, the genesis
and development process is believed to replicate skeletal bone
formation [8]. Exposure of vascular smooth muscle cells (VSMCs)
to a high-phosphate environment, resembling the pathophysio-
logical state in CKD patients, has been demonstrated to initiate
their transdifferentiation to osteoblast-like cells and perform a
cellular program which regulates the process of bone matrix de-
position in vessel wall [9,10].
A number of factors have been evidenced to be crucial for os-
teogenesis and bone remodeling. Among them, Runx2 and WNT/
β-catenin signaling are especially indispensible, since they are
functionally connected elements of a pathway that is necessary for
the commencement of osteoblast differentiation [11–13]. Belong-
ing to the transcription factor family of runt homology domain,
Runx2 is an acknowledged master transcription factor in osteo-
blast precursor cells and has been recognized as the earliestnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proteins is through plasma membrane Frizzled (FZD) receptors
and coreceptors, members of low density lipoprotein receptor-
related protein-5/6 (LRP5/6). Once coupling with their receptors/
coreceptors, WNTs evoke cascaded downstream signaling events,
resulting in the dephosphorylation and stabilization of β-catenin,
which leads to β-catenin translocation into the nucleus, where it
interacts with its DNA-binding partner, i.e. T cell factor (TCF)/
lymphoid enhancer-binding factor (LEF), to initiate the transcrip-
tion of WNT targeted genes [14–16]. In this WNT/β-catenin sig-
naling pathway, it is the inhibition of glycogen synthase kinase 3
(GSK3) rendering a decreased phosphorylation of β-catenin on
Ser33/Ser37/Thr41 sites and a reduced degradation of β-catenin,
that is responsible for the stabilization and activation of β-catenin.
In addition, phosphorylation of β-catenin on Ser675 site by protein
kinase A (PKA) or p21-activated kinase 1 (PAK1) also leads to β-
catenin activation [17–19]. It is well known that WNT/β-catenin
signaling is essential for the osteogenic differentiation of plur-
ipotent mesenchymal cells. Activation of WNT/β-catenin signaling
by pro-osteogenic factors leads to Runx2 induction, which in turn,
regulates pivotal processes essential for osteoblast differentiation
and phenotypic characterization through governing the expression
of several bone-related proteins, such as osterix, osteocalcin, and
sclerostin [8,12,13,20,21].
WNT/β-catenin signaling has been demonstrated to be in-
volved in the high-phosphate-induced VSMCs osteogenic trans-
differentiation (VOT) and the development of AMC [22–27]. Acti-
vation of the Runx2 promoter through a TCF site was observed in
mouse osteoprogenitor cells in vitro [12]. However, the cell-spe-
ciﬁc transcriptional mechanism through which WNT/β-catenin
signaling promotes Runx2 expression in VSMCs and VOT has yet to
be identiﬁed.
In this study, we demonstrate that Runx2 is induced and β-
catenin is activated in the VSMCs in a high-phosphate environ-
ment both in vitro and in vivo. High-phosphate may promote WNT
secretion, and then activate β-catenin via different pathways. Ac-
tivation of WNT/β-catenin signaling, through ectopic expression of
stabilized β-catenin, inhibition of GSK-3β, or WNT-3A protein,
induces Runx2 expression in VSMCs. WNT-3A also promotes os-
teocalcin induction and calciﬁcation of VSMCs. Blockade of WNT/
β-catenin signaling by DKK1 inhibits Runx2 induction and calcium
deposition stimulated by high-phosphate in VSMCs. We further
demonstrate that WNT/β-catenin signaling is responsible for
Runx2 induction in VSMCs. Our studies identify Runx2 as a direct
downstream target of WNT/β-catenin signaling during the high-
phosphate-triggered VOT and unravel a potential mechanism un-
derlying this signal pathway in the pathogenesis of AMC in CKD
patients.2. Material and methods
2.1. Cell culture and treatment
Primary rat aortic smooth muscle cells (p-VSMCs) were isolated
and cultured as described previously [28]. Brieﬂy, prepubertal
male Sprague-Dawley rats purchased from Shanghai Experimental
Animal Center (Shanghai, China) were anesthetized by sodium
pentobarbital, and exsanguinated for euthanasia, and the arterial
segments were acquired. After the inner portion was separated
out, the media was cut into 1-mm2 sections and placed in a cell
culture dish with Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 4.5 g/l glucose supplemented with 20% fetal bovine
serum (FBS) and 10 mM sodium pyruvate. Cells migrated from the
explants were cultured in DMEM with 15% FBS. P-VSMCs between
passages 3 and 8 were used in experiments. For high-phosphatetreatment, the cells were seeded at 70% conﬂuence in complete
medium with 15% FBS for 24 h and then serum-starved for 16 h,
followed by incubation with 10 mM β-glycerophosphoricacid (β-
GP) (Sigma-Aldrich, St Louis, MO) for various periods of time. For
some experiments, after serum starvation, cells were either in-
cubated with 10 ng/ml recombinant WNT-3A (cat. no. 1324-
WN010, R&D Systems, Minneapolis, MN) for various periods of
time or different concentration as indicated for 24 h; or pretreated
with 1 nM LGK794 (porcupine inhibitor, cat. no. HY-17545, Med-
chemexpress), 3 μM IM-12 (GSK-3β inhibitor, cat.no. s7566, Sell-
eck), or 100 ng/ml recombinant DKK1 protein (cat.no. 4010-DK-
010, R&D Systems) for 30 min, followed by incubation with or
without 10 mM β-GP for 24 h.
Rat thoracic aorta smooth muscle cell line (L-VSMC, A7r5) was
purchased from the Type Culture Collection of the Chinese Acad-
emy of Sciences (Shanghai, China), cultured in DMEM with 10%
FBS, and used for plasmid transfection.
2.2. Cell calciﬁcation model
The calciﬁcation of VSMCs was induced as described previously
[28]. Brieﬂy, P-VSMCs were cultured in DMEM, supplemented with
15% FBS, 10 mM β-GP, 50 mg/ml ascorbic acid, 107 M insulin,
10 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml strepto-
mycin and neomycin for 8 d. For manipulation the activity of WNT/
β-catenin signaling, WNT-3A (10 ng/ml) or DKK1 (100 ng/ml) was
added without or with β-GP every 3 d.
2.3. Quantiﬁcation of calcium deposition
P-VSMCs cultured in 10 mm dishes were washed twice with
phosphate buffered saline and decalciﬁed with 0.6 M HCl for 24 h.
Calcium content of the supernatant was determined by the
QuantiChrome Calcium Assay Kit (DICA-500, Bioassay Systems,
Hayward, CA). After decalciﬁcation, cells were solubilized with a
solution of 0.1 M NaOH and 0.1% sodium dodecylsulfate, and the
protein content was measured by the BCA protein assay kit
(Thermo Scientiﬁc, Rockford, IL). Calcium content of the cells was
normalized to protein content and expressed as μg/mg protein.
2.4. Plasmid transient transfection
L-VSMCs seeded in six-well plates at 5105 cells/well were
transfected with Flag-tagged N-terminal truncated, stabilized β-
catenin expression vector (pDel-β-cat) [29] for 48 h by using Li-
pofectamine 2000 (Invitrogen, Carlsbad, CA), and the empty vector
pcDNA3 (Invitrogen) was used as a mock transfection control. For
some experiments, L-VSMCs were transient transfected with
pcDNA3 or pDel-β-cat for 48 h, followed by treated with or
without 10 mM β-GP for 24 h.
2.5. Reporter plasmid construction and site-directed mutagenesis
Runx2 promoter-luciferase reporters were constructed by
cloning different lengths of the Runx2 promoter region into the
pGL3-Basic luciferase vector (Promega, Madison, WI). Different
lengths of the rat Runx2 gene promoter fragments were generated
by using PCR and cloned into the pGL3-Basic luciferase vector
using routine cloning procedures. The correct sequences of the
Runx2 promoter-luciferase constructs were conﬁrmed by DNA
sequencing at the Zoonbio Biotechnology (Nanjing, China) DNA
sequencing core facility. For generating mutant Runx2 promoter-
luciferase reporter, either two points mutation (T to C, and G to T)
at the TCF binding element (TBE) 1, or two points mutation (T to C,
and G to C) at the TBE2, or all of the four points mutation were
introduced in the 1.0kRunx2-Luc reporter plasmid by using site-
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manufacturer (QuikChange II XL kit; Stratagene, La Jolla, CA).
Mutations were conﬁrmed by DNA sequencing.
2.6. Luciferase assay
L-VSMCs were cotransfected by using Lipofectamine 2000 re-
agent with various Runx2-Luc luciferase reporter constructs
(1.0 μg) plus active β-catenin expression vector β-cat(S37A) [30] or
empty pcDNA3 vector (2.0 μg), respectively. A ﬁxed amount
(0.1 μg) of internal control reporter Renilla reniformis luciferase
driven under a thymidine kinase promoter (pRL-TK; Promega) was
also cotransfected for normalizing the transfection efﬁciency. In
some experiments, the transfected cells were incubated with dif-
ferent concentration of β-GP or WNT-3A as indicated. Luciferase
assay was carried out using a dual luciferase assay system kit ac-
cording to the manufacturer's protocols (Promega). Relative luci-
ferase activity was reported as fold induction over controls after
normalizing for transfection efﬁciency.
2.7. Animal model
Male Sprague-Dawley rats weighted approximately 300–400 g
were purchased from Shanghai Experimental Animal Center
(Shanghai, China). They were housed in the animal facilities of the
Experimental Animal Center of Nanjing Medical University with
free access to food and water. Rat model of CRF with AMC was
established according to the protocol described previously
[6,31,32]. Brieﬂy, male Sprague-Dawley rats were fed with a diet
containing 0.75% adenine (Sigma-Aldrich) and 0.9% phosphorus.
Rats fed with standard diet were used as normal controls. At 4 and
6 w after adenine-fed diet, groups of rats (n¼4) were killed and
aorta tissue and serum were collected for various analyses. Ani-
mals were treated humanely in accordance with the National
Medical Advisory Committee Guidelines and the animal protocols
were approved by the Institutional Animal Care and Use Com-
mittee at the Nanjing Medical University.
2.8. Alizarin red S staining and von Kossa staining
For determination of the calcium deposition in VSMCs,
P-VSMCs after various treatment were incubated with 10% neutral
buffered formalin for 10 min, followed by incubation with 2%
aqueous alizarin red S solution (pH4.2) for 15 min.
For evaluation of the aortic calciﬁcation, parafﬁn-embedded
artery sections (3 μm thickness) were prepared by a routine pro-
cedure. The sections were stained with 5% silver nitrate solution in
a glass coplin jar placed under ultraviolet light for 1 h. Un-reacted
silver was removed with 5% sodium thiosulfate for 5 min. Counter
staining was performed in nuclear fast red for 2 min.
2.9. Western Blot analysis
The preparation of whole cell lysates and aorta tissue homo-
genates and Western blot analysis of protein expression were
carried out by using established procedures as described pre-
viously [33]. The primary antibodies were obtained from the fol-
lowing sources: anti-Runx2 (ab76956; Abcam, Cambridge, MA),
anti-dephosphorylated, active β-catenin (anti-ABC, clone 8E7, cat.
no. 05-665; Merck Millipore, Billerica, MA), anti-phospho-β-cate-
nin (Ser675) (#9567; Cell Signaling Technology, Beverly, MA), anti-
β-catenin (cat. no. 610154; BD Transduction Laboratories, San Jose,
CA), anti-Flag (M2, F3165; Sigma), anti-phospho-LRP6 (Ser1490)
(#2568; Cell Signal), anti-LRP6 (C5C7) (#2560; Cell Signal), anti-β-actin (sc-1616; Santa Cruz Biotechnology, Dallas, TX), anti-TATA-
binding protein (TBP) (ab181-100; Abcam), and anti-glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) (sc-25778; Santa
Cruz).
2.10. Real-time RT-PCR
Total RNA isolation and real-time RT-PCR were performed by
the procedures described previously [34]. Brieﬂy, the ﬁrst strand
cDNA synthesis was carried out by using a reverse transcription
system kit (Toyobo, Osaka, Japan) according to the manufacturer's
instructions. Real-time RT-PCR was performed on an ABI
PRISM7300 sequence detection system (Applied Biosystems, Fos-
ter City, CA). The 25 μl volume of PCR reaction mixture contained
12.5 μl 2 SYBR Green PCR Master Mix, 5 μl diluted (1:10) reverse
transcriptase product, and 0.5 μM sense and antisense primer sets.
The sequences of the primer pairs were as follows: Runx2, 5′-TGT
GTG CCT CCA ACC TGT GT-3′ (sense) and 5′-CTT TCC CCC TCA ATT
TGT GTC A-3′ (antisense); GAPDH, 5′-CAG CAA GGA TAC TGA GAG
CAA GAG-3′ (sense) and 5′-GGA TGG AAT TGT GAG GGA GAT G-3′
(antisense). The Runx2 mRNA levels were calculated after nor-
malizing with GAPDH.
2.11. Immunoﬂuorescence staining
Immunoﬂuorescence staining was carried out by using a rou-
tine procedure [34]. Brieﬂy, cells cultured on coverslips were ﬁxed
with methanol and acetone (1:1) for 10 min at 20 °C. After
blocking with 20% normal donkey serum for 30 min, cells were
incubated with the speciﬁc primary antibodies against Runx2 and
β-catenin, and then were stained with FITC- or cyanine Cy3-con-
jugated secondary antibody. Cells were double stained with 4′,
6-diamidino-2-phenylindole-HCl for visualizing the nuclei. Stained
cells were mounted and viewed with a Nikon Eclipse 80i Epi-
ﬂuorescence microscope equipped with a digital camera (DS-Ri1,
Nikon).
2.12. Immunohistochemical staining
Immunohistochemical staining of aorta sections was per-
formed by an established protocol [28]. Parafﬁn-embedded sec-
tions were stained with anti-Runx2 or anti-β-catenin antibody
using the Vector M.O.M. immunodetection kit (Vector Labora-
tories, Burlingame, CA), according to the instructions of manu-
facturer. Slides were viewed under a Nikon Eclipse 80i microscope
equipped with a digital camera (DS-Ri1, Nikon). The primary an-
tibody was replaced by nonimmune normal control IgG as nega-
tive control, and no staining occurred.
2.13. Serum biochemistry
Serum concentrations of serum urea nitrogen, creatinine, in-
organic phosphorus, and total calcium were measured by auto-
mated analyzer in the Center for Kidney Disease in the 2nd Af-
ﬁliated Hospital of Nanjing Medical University.
2.14. Statistical analysis
Statistical analysis of the data was performed using SigmaStat
software (Jandel Scientiﬁc Software, San Rafael, CA). Comparisons
between groups were made using one-way analysis of variance,
followed by the Student-Newman-Keul's test. A p value of o0.05
was considered signiﬁcant.
Fig. 1. β-GP stimulates Runx2 induction and activates β-catenin signaling in VSMCs. (A-C) β-GP induces Runx2 expression in VSMCs. VSMCs were treated with 10 mM β-GP
for various periods of time as indicated, and the cell lysates were immunoblotted with antibodies against Runx2 and β-actin, respectively. A representative Western blot
(A) and the quantitative data (B) are shown. *, po0.05, **, po0.01 versus without β-GP (n¼3). Immunoﬂuorescence staining shows Runx2 expression and localization in
VSMCs incubated with 10 mM β-GP for 24 h. Arrowheads indicate positive nuclear staining of Runx2 (C). (D, E) β-GP induces β-catenin activation in VSMCs. VSMCs were
treated with 10 mM β-GP for various periods of time as indicated, and the cell lysates were immunoblotted with antibodies against active β-catenin (D), phospho-β-catenin
(Ser675) (E), and total β-catenin (D, E), respectively. (F-H) High-phosphate induces β-catenin nuclear translocation in VSMCs. VSMCs were treated with 10 mM β-GP for 3 or
6 h, and nuclear and cytoplasmic protein from VSMCs were prepared and immunoblotted with antibodies against β-catenin, TBP or GAPDH, respectively. The ratios of β-
catenin per control proteins (TBP for nuclear protein and GAPDH for cytoplasmic protein) are shown (F, G). Immunoﬂuorescence staining shows β-catenin expression in
VSMCs treated with 10 mM β-GP for 6 h. Arrowheads denote nuclear localization of β-catenin (H). (I) β-GP induces LRP6 phosphorylation. VSMCs were treated with 10 mM β-
GP for various periods of time as indicated, and the cell lysates were immunoblotted with antibodies against phospho-LRP6 (Ser1490) and LRP6 (C5C7), respectively.
(J) Inhibition of PORCN abolishes Runx2 induction stimulated by β-GP. VSMCs were pretreated with LGK 974 (1 nM) for 30 min, then incubated with β-GP (10 mM) for 24 h,
and the cell lysates were immunoblotted with antibodies against Runx2 and β-actin, respectively. β-GP, β-glycerophosphoric acid; CTL, control; DAPI, 4′, 6-diamidino-2-
phenylindole-HCl; TBP, TATA-binding protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LRP, low density lipoprotein receptor-related protein.
T. Cai et al. / Experimental Cell Research 345 (2016) 206–217 2093. Results
3.1. β-GP induces Runx2 expression and WNT/β-catenin signaling
activation in VSMCs
Induction of osteogenic genes, such as Runx2, is one of the main
features of VOT in a high-phosphate environment. We ﬁrst ex-
amined the expression of Runx2 by incubating VSMCs with β-GP, a
donor of organic phosphate [28]. As shown in Fig. 1A, β-GP
markedly induced Runx2 expression in a time-dependent manner.
Quantitative determination revealed a 2.5-fold induction of Runx2
protein at 24 h after β-GP (10.0 mM) treatment in VSMCs (Fig. 1B).
Immunoﬂuorescence staining exhibited a notable, nuclear locali-
zation of Runx2 in VSMCs stimulated by β-GP (Fig. 1C, arrow-
heads), whereas the staining for Runx2 at basal condition was
weak and misty in cytoplasm (Fig. 1C).Several studies have shown that WNT/β-catenin signaling is
involved in the pathogenesis of VOT [23–26], which motivated us
to explore whether this signal pathway plays a role in mediating
β-GP-induced Runx2 expression in VSMCs. For this purpose, we
investigated the regulation of β-catenin activity by β-GP. As shown
in Fig. 1D and E, β-GP stimulated β-catenin activation in VSMCs, as
revealed by the upregulation of both dephosphorylated (Ser37/
Thr41) β-catenin (Fig. 1D) and phosphorylated (Ser675) β-catenin
(Fig. 1E). Given that either dephosphorylation on Ser37/Thr41 sites
or phosphorylation on Ser675 site induces β-catenin translocation
into the nuclei and increases its transcriptional activity [17,18], we
next tested whether β-GP induced β-catenin nuclear translocation,
an obligatory step for β-catenin to govern its target gene tran-
scription. As shown in Fig. 1F, treatment with β-GP promoted β-
catenin nuclear translocation in VSMCs. Of note, although β-GP
caused a predominant increase of β-catenin in nuclei, the
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(Fig. 1G), and the total β-catenin levels were little affected (Fig. 1D
and E). Immunoﬂuorescence staining exhibited nuclear localiza-
tion of β-catenin in VSMCs incubated with β-GP (10.0 mM) for 6 h
(Fig. 1H, arrowheads), whereas β-catenin located in cell-cell
junction and cytoplasm under basal circumstance (Fig. 1H). Hence,
high-phosphate induced Runx2 expression along with activation
of β-catenin in VSMCs.
In order to conﬁrm WNT/β-catenin signaling involving in the
induction of Runx2 by high-phosphate, we tested two crucial steps
in upstream of this signaling. One is phosphorylation of LRP6,
another is secretion of WNT. As one of coreceptors for WNT, LRP6
is required for WNT/β-catenin signaling. Upon stimulation with
WNT, LRP6 is phosphorylated at multiple sites including Thr1479,
Ser1490 and Thr1493 [35,36]. As shown in Fig. 1I, it seemed that
the phosphorylation of LRP6 (Ser1490) was induced within 3 h
after β-GP treatment in VSMCs. This result suggests that high-
phosphate may evoke the enhancement of autocrine WNT because
LRP6 phosphorylation is WNT-dependent, so we next assessed the
necessity of WNT secretion for high-phosphate-induced Runx2
expression. To this end, VSMCs were treated with LGK974, a potent
and speciﬁc small molecule PORCN inhibitor, followed by incuba-
tion with β-GP. As an o-acyltransferase, PORCN is required for
palmitoylation of WNT ligands, an indispensable step in the pro-
cessing of WNT ligand secretion [37]. As shown in Fig. 1J, inhibi-
tion of PORCN abolished Runx2 induction by β-GP in VSMCs
(Fig. 1J, lane4 versus lane2). Considered together, high-phosphate
appears to activate WNT/β-catenin signaling in VSMCs via pro-
moting WNT secretion.Fig. 2. Activation of β-catenin signaling promotes Runx2 induction in VSMCs. (A-C) Ec
transiently transfected with either empty vector (pcDNA3) or Flag-tagged, N-termina
munoblotted with antibodies against Flag, Runx2, and β-actin, respectively. A representa
pcDNA3 controls (n¼3). Immunoﬂuorescence staining shows Runx2 expression in VSM
nuclear staining of Runx2 in VSMCs (C). (D, E) Exogenous β-catenin couldn't further p
transfected with either pcDNA3 or pDel-β-cat for 24 h, and followed by treatment with o
quantitative data (E) are shown. *, po0.05 versus pcDNA3 without β-GP. #, p40.05 vers
VSMCs were treated with or without IM-12 (3 μM) for 24 h, and cells treated with β-G
antibodies against Runx2 and β-actin, respectively. β-GP, β-glycerophosphoric acid; DAP3.2. Activation of β-catenin signaling mediates Runx2 induction in
VSMCs
To determine any involvement of β-catenin activation in Runx2
regulation, VSMCs were transiently transfected with Flag-tagged,
N-terminal truncated, stabilized β-catenin expression vector
(pDel-β-cat) [29] or empty vector (pcDNA3). As shown in Fig. 2A,
elevated level of exogenous stabilized β-catenin in the VSMCs
transfected with pDel-β-cat was evident, as presented by Western
blot analysis using anti-Flag antibody, and ectopic expression of
stabilized β-catenin resulted in Runx2 induction. To address
whether Runx2 induction by β-catenin activation is a general
phenomenon, we also examined Runx2 expression in the VSMCs
transiently transfected with another stabilized β-catenin expres-
sion vector (β-cat(S37A)) [30] and got a similar result (data not
shown). Quantitative determination revealed an approximate
three-fold induction of Runx2 expression in the VSMCs transfected
with pDel-β-cat, compared with that transfected with pcDNA3
(Fig. 2B). Immunoﬂuorescence staining presented a remarkable
nuclear localization of Runx2 in the VSMCs overexpressing stabi-
lized β-catenin (Fig. 2C, arrows). However, it seemed that exo-
genous stabilized β-catenin couldn't further promote Runx2 in-
duction at β-GP-stimulated conditions (Fig. 2D, lane4 versus lane2
and lane3, respectively, and Fig. 2E).
Given that the inhibition of the β-catenin degradation complex
can be achieved by direct inhibition of GSK-3β, we assessed the
effect of IM-12, a selective small molecule GSK-3β inhibitor [38],
on Runx2 induction in VSMCs. We found that activation of β-ca-
tenin signaling through the inhibition of GSK-3β also induced thetopic expression of stabilized β-catenin promotes Runx2 induction. L-VSMCs were
l truncated β-catenin vector (pDel-β-cat) for 48 h, and the cell lysates were im-
tive Western blot (A) and the quantitative data (B) are presented. *, po0.05 versus
Cs transfected with either pcDNA3 or pDel-β-cat for 48 h. Arrows indicate positive
romote Runx2 induction at β-GP-stimulated conditions. L-VSMCs were transiently
r without 10 mM β-GP for another 24 h. A representative Western blot (D) and the
us pDel-β-cat with β-GP (n¼3). (F) Inhibition of GSK-3β promotes Runx2 induction.
P (10 mM) were as a positive control. The cell lysates were immunoblotted with
I, 4′, 6-diamidino-2-phenylindole-HCl.
Fig. 3. Runx2 gene promoter contains two functional TBEs which are responsible for β-catenin-mediated Runx2 induction in VSMCs. (A) Diagram shows the construction of
the luciferase reporter plasmid containing the promoter region of rat Runx2 gene linked to the coding sequence of luciferase. Putative two TBE sites are indicated. (B) L-
VSMCs were cotransfected with the luciferase reporter plasmid (1.0kRunx2-Luc or 0.5kRunx2-Luc) and either empty vector (pcDNA3) or stabilized β-catenin vector (β-cat
(S37A)) for 48 h. Luciferase activities show that Runx2 promoter contains at least one functional TBE (1.0kRunx2-Luc) that is responsive to β-catenin stimulation. (C, D) site-
directed mutation in either (mutant-1 in TBE1 or mutant-2 in TBE2) or both (mutant-1 and 2) of two TBEs of Runx2 promoter abolishes its responsiveness to β-catenin
stimulation. The construction of wild-type and mutant TBE reporter plasmids (C) and luciferase activities (D) are presented. *, po0.01 versus pcDNA3 controls; §, po0.01
versus cotransfected with β-cat(S37A) and wile type luciferase reporter plasmid (1.0kRunx2-Luc) (n¼3). (E, F) High-phosphate or WNT-3A enhances Runx2 luciferase
reporter activity. L-VSMCs were transfected with the luciferase reporter plasmid (1.0kRunx2-Luc). Twenty-four hours after transfection, the cells were incubated with various
concentrations of β-GP (E) or WNT-3A protein (F) as indicated. *, po0.01 versus vehicle controls (n¼3).
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3.3. Runx2 gene promoter contains two functional TCF binding sites
responsible for β-catenin action
To elucidate the mechanism underlying β-catenin regulation of
Runx2 expression in VSMCs, we analyzed the structure and func-
tion of rat Runx2 gene promoter. Bioinformatics analysis revealed
two putative TCF-binding sites (TBE1 and TBE2) in the proximalpromoter region of the rat Runx2 gene (Fig. 3A). To test the func-
tionality of these TBEs, we constructed two luciferase reporter
plasmids containing different lengths of the promoter region of
the rat Runx2 gene linked to the coding sequence of luciferase
gene. After these constructs were cotransfected into VSMCs with
empty vector pcDNA3 or stabilized β-catenin expression vector β-
cat(S37A) [30], luciferase activities were assessed. As shown in
Fig. 3B, at least one functional TBE, located at 1000bp to 500bp
relative to transcription initiation site, was responsive to the
T. Cai et al. / Experimental Cell Research 345 (2016) 206–217212stimulation from β-catenin. Deletion of this region abolished lu-
ciferase induction by β-catenin (Fig. 3B). To conﬁrm the im-
portance of these TBEs in regulating Runx2 expression, we utilized
a site-directed mutagenesis approach to introduce two points
mutation in the TBE1 (T to C, and G to T) and TBE2 (T to C, and G to
C), respectively (Fig. 3C). As shown in Fig. 3D, damage of each of
two TBEs largely attenuated its susceptibility to β-catenin stimu-
lation, while destruction both of them by introducing all of these
four points mutation almost completely abolished its responsive-
ness to β-catenin.
Next, we tested the effect of high-phosphate on Runx2 pro-
moter activity. We found that β-GP stimulated Runx2 promoter
activity in a dose-dependent manner in VSMCs after transfection
with Runx2 promoter-luciferase reporter plasmid (1.0kRunx2-Luc)Fig. 4. WNT/β-catenin signaling modulates VSMCs osteogenic transdifferentiation and ca
with different concentrations of WNT-3A for 24 h or 10 ng/ml WNT-3A for various period
(B, D) are shown. *, po0.05,**, po0.01 versus without WNT-3A (n¼3). (E, F), DKK1 inhib
ml) for 30 min, then incubated with β-GP (10 mM) for 24 h. A representative Western bl
po0.01 versus without DKK1 (n¼3). (G) Activation of WNT/β-catenin signaling by either
with 10 mM β-GP or 10 ng/ml WNT-3A for 6 d, and the cell lysates were immunoblotted
signaling modulates VSMCs calciﬁcation. VSMCs were treated with various stimulators f
quantitative method (I) in VSMCs are presented. a, Vehicle; b, 10 mM β-GP; c, 10 ng/ml W
§, po0.05 versus β-GP alone (n¼3).(Fig. 3E). This result is consistent with the induction of Runx2
protein by β-GP (Fig. 1A), suggesting that high-phosphate, through
activation of WNT/β-catenin signaling, is able to activate Runx2
promoter and induce its gene expression. Since WNT is the up-
stream activator of β-catenin signaling, we examined the effect of
WNT-3A, the prototypic WNT that transmits its signal via β-cate-
nin-dependent signaling, on Runx2 promoter activity in VSMCs. As
shown in Fig. 3F, the activation of β-catenin signaling by WNT-3A
also induced Runx2 promoter activity in VSMCs.
3.4. WNT/β-catenin signaling modulates VSMCs osteogenic trans-
differentiation and calciﬁcation in vitro
To provide further evidence for a role of β-catenin-dependentlciﬁcation in vitro. (A-D) WNT-3A promotes Runx2 expression. VSMCs were treated
s of time as indicated. Representative Western blots (A, C) and the quantitative data
its Runx2 expression induced by β-GP. VSMCs were pretreated with DKK1 (100 ng/
ot (E) and the quantitative data (F) are presented. *, po0.01 versus without β-GP; §,
β-GP or WNT-3A upregulates osteocalcin expression in VSMCs. VSMCs were treated
with antibodies against osteocalcin and β-actin, respectively. (H, I) WNT/β-catenin
or 8 d. Alizarin red S staining (H) and the results of calcium content measured by a
NT-3A; and d, 10 mM β-GP with 100 ng/ml DKK1. *, po0.05 versus vehicle controls;
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effect of WNT-3A on Runx2 expression in VSMCs. As shown in
Fig. 4A and C, Runx2 was induced in VSMCs treated with re-
combinant WNT-3A protein in a dose- or time-dependent manner.
Quantitative determination displayed a three- to four-fold induc-
tion of Runx2 protein at 24 h after WNT-3A (10 ng/ml) treatment
in VSMCs (Fig. 4B and D). For assessing the necessity of WNT/β-
catenin signaling activation for β-GP-induced Runx2 expression,
we further investigated the inhibitory effect of WNT antagonist
DKK1, a natural inhibitor of WNT/β-catenin signaling by the spe-
cialty to interact with and block LRP5/6 coreceptor, on the in-
duction of Runx2 in VSMCs stimulated by β-GP. For this purpose,
VSMCs were treated with recombinant DKK1 protein (100 ng/ml),
followed by incubation with β-GP. As shown in Fig. 4E and F, in-
hibition of WNT/β-catenin signaling attenuated Runx2 induction
by β-GP in VSMCs.
We next observed the inﬂuence of WNT/β-catenin signaling
activation on the expression of osteocalcin, a bone-related protein
which is downstream of Runx2, in VSMCs. As shown in Fig. 4G,
WNT-3A promoted osteocalcin induction in VSMCs, similar to the
effect of β-GP. We further investigated the effect of WNT/β-catenin
signaling on calciﬁcation in VSMCs. As displayed in Fig. 4H, acti-
vation of WNT/β-catenin signaling by WNT-3A induced calcium
deposition in VSMCs (Fig. 4H, c versus a), similar to the effect
produced by β-GP (Fig. 4H, c versus b), whereas inhibition of WNT/
β-catenin signaling by DKK1 markedly abolished calcium deposi-
tion stimulated by β-GP (Fig. 4H, d versus b). By using a quanti-
tative method, we examined the calcium contents in VSMCs
treated with various stimulators and found the similar results
(Fig. 4I). Therefore, it is suggested that WNT-3A, through activation
of its downstream mediator β-catenin, is able to induce Runx2 and
osteocalcin expression and promote calciﬁcation in VSMCs. Con-
versely, blockade of WNT/β-catenin signaling by DKK1 inhibits
Runx2 induction and calcium deposition stimulated by β-GP.
3.5. Runx2 expression is positively associated with β-catenin acti-
vation in the aortic wall of CRF rats
To investigate the potential relationship of activity of WNT/β-Fig. 5. Arterial medial calciﬁcation is induced in rats with chronic renal failure. (A-D) M
media of the aorta in rats with chronic renal failure (CRF). Aortic section from the norma
staining. Scale bar, 500 mm (A, B); 50 mm (C, D). (E) The quantitative data of serum urea ni
(n¼4).catenin signaling to Runx2 expression in vivo, we established CRF
with AMC model in rats. The adenine-fed rats had severe renal
failure, with a remarkable increase in serum creatinine
(5.3771.29 mg/dl and 4.6470.23 mg/dl in 4 and 6 w adenine-fed
rats versus 1.6670.23 mg/dl in controls, respectively) and serum
urea nitrogen (132.46728.34 mg/dl and 169.99716.63 mg/dl,
versus 24.5371.13 mg/dl, respectively) (Fig. 5E). The 4 and 6 w
adenine-fed rats showed an evident increase in serum phosphorus
(5.9270.74 mmol/l and 6.3070.78 mmol/l) compared with con-
trols (2.4570.02 mmol/l) (Fig. 5E), similar to a previous report
[32]. Histological assessment using von Kossa staining displayed
that the aortic wall in 6 w adenine-fed rats had extensive linear
calciﬁcation, which was localized in the aortic media, resembling
the typical Mönckeberg's pattern (Fig. 5B versus A, and D versus C).
Then, we examined Runx2 and β-catenin protein expression
and localization in the aortic wall of 4 w CRF rats. Im-
munohistochemical staining showed that Runx2 expression was
mainly induced in the aortic media of CRF rats compared with
controls (Fig. 6B versus A). Meanwhile, the cell numbers of positive
β-catenin staining were markedly increased in the aortic wall of
CRF rats compared with controls (Fig. 6D versus C, and F versus E),
and β-catenin was predominantly localized in the nuclei of VSMCs
in the media of aorta (Fig. 6F, arrowheads). Consistently, Runx2
mRNA expression was remarkable upregulation in the aortic wall
of 4 and 6 w CRF rats, as compared with the normal controls,
which was determined by quantitative real-time RT-PCR approach
(Fig. 6G). Next, we investigated the expression of depho-
sphorylated β-catenin (Ser37/Thr41) and phosphorylated β-cate-
nin (Ser675), two active forms of β-catenin, in the aortic wall of
various groups. Western blot analysis showed a dramatic increase
in both of them despite exhibiting in different expression patterns
(Fig. 6H and I). Quantitative determination indicated approxi-
mately six-fold induction of the relative abundance of phos-
phorylated β-catenin (Ser675) protein in the aortic wall of 4 w CRF
rats, when compared with that in the normal controls (Fig. 6J).
Linear regression showed a positive correlation between Runx2
mRNA level and phosphorylated β-catenin (Ser675) abundance
(Fig. 6K). These observations suggest that β-catenin activation may
implicate in Runx2 induction and osteogenic transdifferentiationorphological assessment presents the extensive calcium deposition in the tunica
l controls (A, C) and adenine-fed 6 w CRF rats (B, D) were processed with von Kossa
trogen, creatinine, inorganic phosphorus and total calcium in each group are shown.
Fig. 6. Runx2 expression is positively correlated with β-catenin activation in the aortic wall of rats with chronic renal failure. (A-F) Immunohistochemical staining shows the
expression and localization of Runx2 (A, B) and β-catenin (C-F) protein in the aortic wall of control rats and CRF rats, respectively. Aortic sections from normal controls (A, C)
and adenine-fed 4 w CRF rats (B, D) were immunostained with antibodies against Runx2 and β-catenin, respectively. Scale bar, 50 mm (A, B); 100 mm (C, D). Enlarged image
from the boxed area in C and D are shown (E, F) and the arrowheads indicate β-catenin positive cells (F). (G) Quantitative, real-time RT-PCR analyses show the mRNA levels of
Runx2 in each group. *, po0.05 versus controls (CTL) (n¼4). (H, I) β-catenin is activated in the aortic wall of rats with CRF. The aortic tissue lysates from each group were
immunoblotted with antibodies against active β-catenin (H), phospho-β-catenin (Ser675) (I) and β-actin, respectively. (J) The quantitative data of Western blot analysis for
phospho-β-catenin (Ser675) are presented. *, po0.05 versus controls (n¼4). (K) Linear regression shows a positively correlation between aortic Runx2 mRNA levels and
phospho-β-catenin(Ser675) abundance (arbitrary units). The correlation coefﬁcient (R2) is shown.
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AMC.4. Discussion
It has been demonstrated that WNT/β-catenin signaling pro-
motes osteogenesis by directly stimulating Runx2 gene expression
[12]. However, the cell-speciﬁc transcriptional mechanism through
which this signaling regulates Runx2 expression in VSMCs remainsincompletely understood. Our ﬁndings in present study suggest
that Runx2 is a transcriptional target of WNT/β-catenin signaling
pathway in the VSMCs undergoing VOT in a high-phosphate en-
vironment. Evidence suggestive of this conclusion is as follows.
First, Runx2 expression is induced and β-catenin is activated by
high-phosphate, and activation of β-catenin signaling by over-
expressing stabilized β-catenin or inhibiting GSK-3β induces
Runx2 expression in VSMCs. Second, the Runx2 gene promoter
region contains two TBEs, which functionally mediate the inter-
action with TCF in response to β-catenin activation. Third,
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whereas inhibition of WNT/β-catenin signaling by PORCN in-
hibitor or DKK1 attenuates Runx2 induction stimulated by high-
phosphate in VSMCs. Fourth, WNT-3A upregulates osteocalcin
expression and promotes calcium deposition in VSMCs, whereas
DKK1 inhibits VSMCs calciﬁcation induced by high-phosphate.
Finally, in CRF rats, β-catenin is activated and Runx2 is induced in
the aortic tunica media, followed by AMC, and the Runx2 mRNA
level is positively correlated with the abundance of active β-ca-
tenin in the aortic wall. Given that high-phosphate activates β-
catenin in VSMCs, this signal pathway likely plays a critical role in
mediating high-phosphate-triggered Runx2 induction. Our studies
provide signiﬁcant insights into the role and mechanism of WNT/
β-catenin signaling in regulation of Runx2 expression during VOT.
Furthermore, these results suggest that Runx2 induction could
play an essential role in mediating the action of WNT/β-catenin
signaling in promoting vascular calciﬁcation.
Vascular calciﬁcation has been recognized to occur as a con-
sequence of the processes similar to bone formation [2,3]. As a cell
type derived from mesenchymal cell, VSMCs under stress can
differentiate to other mesenchymal origin cell types, such as os-
teoblasts. At the site of calciﬁcation, VSMCs undergo a phenotypic
change to osteoblast-like cells with upregulating the expression of
several bone-related proteins, which are normally conﬁned to
regulate the procedure of mineralization in bone [39]. These pro-
teins include a number of transcription factors, such as Runx2,
Osterix, Msx2, and Sox9, which are involved in the differentiation
of VSMCs to an osteoblastic phenotype [39]. As previously de-
monstrated by us [28] and other researchers [24,25,27,40–42],
VSMCs cultured in high-phosphate undergo VSMCs to osteogenic
transdifferentiation (VOT) and calciﬁcation. As a master osteoblast
transcription factor and the earliest osteoblastic marker, Runx2 has
been generally recognized as an early feature of VOT [24,25,27,28].
This notion is further strengthened by present study exhibiting
that Runx2 is markedly induced in the VSMCs in a high-phosphate
environment both in vitro and in vivo (Fig. 1A through C, 6B, G and
H), especially in the nuclei of the VSMCs (Fig. 1C, arrowheads).
WNT/β-catenin signaling has been implicated in the regulation
of high-phosphate-induced VOT and calciﬁcation of VSMCs [23–
27,43]. Several studies indicate that high-phosphate can activate
β-catenin signaling, which is evidenced by the upregulation of β-
catenin expression [25,26], the decrease of phosphorylated β-ca-
tenin (Ser33/37/Thr41) [26], or the translocation of β-catenin into
the nuclei [24,27] in VSMCs. β-Catenin speciﬁcally plays a two-tier
role in cell function. On the one hand, it is an indispensable
structural component of adherens junctions based on cadherin; on
the other hand, it is the pivotal effector of WNT/β-catenin sig-
naling in the nucleus [35]. If not combined with cadherins, cyto-
plasmic β-catenin is phosphorylated by a multiprotein destruction
complex which is comprised of the scaffold proteins Axin and
adenomatous polyposis coli, casein kinase 1α (CK1α), and glyco-
gen synthase kinase 3 (GSK3). β-Catenin is phosphorylated on
Ser45 site by CK1α and then on Ser33/Ser37/Thr41 sites by GSK3,
making its ubiquitination and proteasomal degradation [35]. So
without a WNT signal, the levels of cytoplasmic free β-catenin are
maintained low. WNT signaling causes the disintegration of the
destruction complex and the inhibition of GSK3 activity, leading to
a reduced phosphorylation of β-catenin on Ser33/Ser37/Thr41
sites, which results in its stabilization, accumulation and sub-
sequent translocation into the nucleus [35]. In addition to this
WNT/β-catenin signaling pathway, phosphorylation of β-catenin
on Ser675 site by either protein kinase A (PKA) [17,18] or p21-
activated kinase 1 (PAK1) [19] promotes TCF-dependent gene
transcription, thereby enhancing the signaling activity of β-cate-
nin. These studies indicated that phosphorylation of β-catenin on
Ser675 site promotes the stability of β-catenin [18,19], or increasesthe recruitment of coactivators of β-catenin-mediated transcrip-
tion, such as CREB binding protein [17]. In present study, it is de-
monstrated that high-phosphate activates WNT/β-catenin signal-
ing in VSMCs, which is conﬁrmed by the translocation of β-catenin
into the nuclei. In addition, what is more interesting is that our
ﬁnding indicates that high-phosphate induces two forms of active
β-catenin both in vitro and in vivo: one is the β-catenin depho-
sphorylated on Ser37/Thr41 sites (Figs. 1D and 6H), another is the
β-catenin phosphorylated on Ser675 site (Figs. 1E, and 6I). This
ﬁnding suggests that high-phosphate may activate WNT/β-catenin
signaling in VSMCs via at least two pathways, which lead to the
inhibition of GSK3 and the activation of PKA or/and PAK1, re-
spectively, resulting in the enhancement of stability and tran-
scriptional activity of β-catenin. However, the potential mechan-
ism that how high-phosphate modulates the activity of these ki-
nases in VSMCs still need be clariﬁed by further studies.
The activity of WNT/β-catenin signaling is dependent on WNT
ligand. In the process of WNT ligand biosynthesis, posttransla-
tional palmitoylation of WNT is mediated by PORCN, which is
required for subsequent WNT secretion. Our ﬁnding suggests that
high-phosphate may activate WNT/β-catenin signaling via en-
hancing the activity of PORCN in VSMCs and promoting WNT li-
gand secretion, which in turn induces the phosphorylation of
LRP6. Likewise, the mechanism of high-phosphate regulating
PORCN in VSMCs also need be cleared by further studies.
One major ﬁnding of present study is the identiﬁcation of
Runx2 as a directly transcriptional target of WNT/β-catenin sig-
naling in VSMCs. Previous study demonstrates that WNT/β-cate-
nin signaling positively regulates Runx2 promoter activity in
mouse osteoprogenitor (MC3T3) cells and embryonic mesenchy-
mal cells prior to the induction of osteoblast phenotypic genes,
and a functional TCF regulatory element responsive to WNT/β-
catenin signaling is determined to reside in the promoter of the
Runx2 gene in MC3T3 cells [12]. In present study, activation of β-
catenin signaling by overexpression of stabilized, depho-
sphorylated β-catenin (β-cat(S37A)) induces Runx2 promoter ac-
tivity in VSMCs. Our ﬁnding identiﬁes two critical TBEs located at
1000bp to 500bp relative to transcription initiation site, which
are responsive to exogenous β-catenin stimulation in VSMCs
(Fig. 3A). Deletion or destruction of both of the TBEs completely
abolishes its responsiveness to β-catenin stimulation (Fig. 3B and
D). Of note, destruction of either of the TBEs is able to largely at-
tenuate its responsiveness to β-catenin signal, suggesting that the
functional response of two TBEs to β-catenin signal seems inter-
active and synergistic. To our knowledge, this is the ﬁrst report
which is unveiling the role of WNT/β-catenin signaling in reg-
ulating Runx2 gene expression in VSMCs.
WNT-3A is an upstream activator in WNT/β-catenin signaling,
while β-GP also has the ability to activate this signaling in VSMCs
according to our ﬁndings in present study (Fig. 1), so it is not
surprising that both factors can stimulate Runx2 promoter activity
(Fig. 3E and F). Given that WNT/β-catenin signaling is inactive in
VSMCs under normal conditions, the high-phosphate-induced
signaling activation suggests that the signaling machinery is ex-
istent in the cells. Previous study demonstrates that several WNT
ligands (e.g. WNT-2B, WNT-10B, and WNT-7A) and other WNT/β-
catenin signaling-related genes, such as receptors, co-receptors,
antagonists, inhibitors, and so on, are expressed detectably in
normal VSMCs [44]. We hypothesize that high-phosphate may
break the balance among these signaling components through
some mechanism, for example, enhancing WNT secretion. Since
multiple ligands and receptors could create combinatorial di-
versity and contribute to variable cellular responses [45], the ac-
tivation of signaling induced by high-phosphate is a comprehen-
sive effect. Therefore, it could be possible that β-GP induces a
stronger Runx2 promoter activity than WNT-3A does (Fig. 3E
T. Cai et al. / Experimental Cell Research 345 (2016) 206–217216versus F).
Our study also suggests that targeting WNT/β-catenin signaling
might be an effective strategy to hinder the progression of VOT
and calciﬁcation of VSMCs under a high-phosphate environment.
DKK proteins speciﬁcally inhibit the WNT/β-catenin signaling
pathway by interacting with the LRP5/6 coreceptor [33], therefore,
our observation that DKK1 inhibits Runx2 induction and calcium
deposition in VSMCs clearly underscores a pivotal role of a hy-
peractive WNT/β-catenin signaling pathway in the pathogenesis of
VOT and calciﬁcation of VSMCs triggered by high-phosphate. It
should be pointed out that the activation of β-catenin signaling
through increasing phosphorylation of β-catenin on Ser675 site
couldn't be abrogated by DKK1. According to the ﬁnding in present
study, downregulation of phosphorylated β-catenin (Ser675)
through inhibiting PKA or/and PKA1 pathway could be an effective
way to partially suppress Runx2 expression, VOT, and in turn,
calciﬁcation of VSMCs induced by high-phosphate. This notion
remains to be veriﬁed by further studies.5. Conclusion
In summery, our present study has demonstrated that Runx2 is
a direct transcriptional target of WNT/β-catenin signaling path-
way. By inducing this main osteoblast transcription factor, WNT/β-
catenin signaling could play a crucial role in promoting VOT and
the development and progression of vascular calciﬁcation. Fur-
thermore, the concomitant induction of two forms of active β-
catenin unveils that the activation of WNT/β-catenin signaling by
high-phosphate may be implemented through different pathways.
Undoubtedly, further investigation on the function and mechan-
ism of high-phosphate in triggering of WNT/β-catenin signaling
activation are hopeful to gain mechanistic insights into VOT and to
offer new clues for designing rational strategies to inhibit the
progression of vascular calciﬁcation in CKD patients.Acknowledgments
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